17,261 trials
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Cancer · Leukemia · Myelodysplastic Syndrome
Primary: Overall Response — 24; 3 participants
Acute Myocardial Infarction
Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Intraocular Melanoma
Primary: Overall Response Rate — 0 patients
Recurrent Breast Carcinoma · Stage IIIB Breast Cancer · Stage IIIC Breast Cancer
Primary: Number of Participants With Response Defined Using Response Evaluation Criteria In Solid Tumors (RECIST) — 0; 1; 20; 0 participants
Prostate Cancer
Primary: Response Rate — 9.3 percentage of participants
Alzheimer's Disease
Primary: Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain — -0.03; 0.02 SUVr — p=0.22
Esophageal Cancer
Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Leukemia · Myelodysplastic Syndromes
Primary: Treatment Efficacy as Defined by Complete or Partial Remission — 1; 5 participants
Sarcoma
Primary: Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment — 52.5; 68.9 percentage of participants
Neoplastic Syndrome
Primary: Complete Response Rate — 2 Participants
Breast Neoplasms
Primary: Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation…